Mechanisms and effects of Abelmoschus manihot preparations in treating chronic kidney disease

Zhongguo Zhongyao Zazhi

Volumn 37, Issue 15, 2012, Pages 2252-2256

  Chen, Ping ^a   Wan, Yigang ^a   Wang, Chaojun ^b   Zhao, Qing ^c   Wei, Qingxue ^c   Tu, Yue ^c   Yin, Xuejiao ^c  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b Kunshan Hospital of Traditional Chinese Medicine   (China)

^c NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Abelmoschus manihot; Chronic kidney disease; Clinical effect; Mechanism

Indexed keywords

ABELMOSCHUS MANIHOT EXTRACT; HUANGKUI; PLANT EXTRACT; UNCLASSIFIED DRUG;

ANAPHYLACTOID PURPURA; ARTICLE; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DRUG MECHANISM; DRUG SYNTHESIS; HEMATURIA; IMMUNITY; IMMUNOGLOBULIN A NEPHROPATHY; INFLAMMATION; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY TUBULE DAMAGE; MEDICINAL PLANT; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; PROTEINURIA;

ABELMOSCHUS; ANIMALS; DRUGS, CHINESE HERBAL; HUMANS; KIDNEY; RENAL INSUFFICIENCY, CHRONIC;

EID: 84867602377     PISSN: 10015302     EISSN: None     Source Type: Journal    
DOI: 10.4268/cjcmm20121514     Document Type: Article

References (41)

1. de Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes(VITAL study) : a randomised controlled trial[J]. Lancet, 2010,376:1543.
2. Baltatzi M,Savopoulos Ch, Hatzitolios A. Role of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in hypertension of chronic kidney disease and renoprotection. study results[J]. Hippokratia, 2011,15(Suppl 1):27.
3. Nakamura H, Mizuno K, Ohashi Y, et al. Pravastatin and cardiovascular risk in moderate chronic kidney disease[J], Atherosclerosis,2009,206:512.
4. Lai X Y, Zhao Y Y, Hong L. A flavonoid glucuronide from Abelmoschus manihot(L.)Medic[J]. Biochem Syst Ecol,2007,35:891.
5. Wen J Y, Chen Z W. Protective effect of pharmacological preconditioning of total flavones of Abelmoschl manihot on cerebral ischemic reperfusion injury in rats[J]. Am J Chin Med,2007,35:653.
6. J Ashley Jefferson, Richard J. Experimental mesangial proliferative glomerulonephritis[J]. J Nephrol,1999,12:297.
7. Couser W G, Johnson R J. Mechanisms of progressive renal disease in glomerulonephritis[J]. Am J Kidney Dis,1994,23:193.
8. Kone B C. Nitric oxide synthesis in the kidney: isofnrms, biosynthesis, and functions in health[J]. Semin Nephrol,2004,24:299.
9. Shaul P W. Regulation of endothelial nitric oxide synthase: location, location, location[J]. Annu Rev Physiol,2002,64:749.
10. Liu Y H. Renal fibrosis: new insights into the pthogenesis and therapeutics[J]. Kidney Int,2006,69:213.
11. Schiffer M, Von Gersdorff G, Bitzer M, et al. Smad proteins and transforming growth factor-beta signaling[J]. Kidney Int,2000,58:S45.
12. Yokozawa T, Dong E, Kawai Y, et al. Protective effects of some flavonoids on the renal cellular membrane[J]. Exp Toxicol Pathol,1999,51:9.
13. Xu X, Fang Y, Ji J. Clinical value of urinary kidney biomarkers for estimation of renal impairment in elderly Chinese with essential hypertension[J]. J Clin Lab Anal,2008,22:86.
14. Palmer B F. Proteinuria as a therapeutic target in patients with chronic kidney disease[J]. Am J Nephrol,2007,27:287.
15. Goldbach-Mansky R, Wilson M, Fleischmann R, et al. Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial[J]. Ann Intern Med,2009,151:229.
16. Marks W H. Tripterygium wilfordii Hook F. versus sulfasalazine in the treatment of rheumatoid arthritis; a well-designed clinical trial of a botanical demonstrating effectiveness[J]. Fitoterapia, 2011,82:85.
17. Li L S, Liu Z H. Epidemiologic data of renal disease from a single unit in China; analysis based on 13,519 renal biopsies[J]. Kidney Int,2004,66:920.